4-(Cyclopentylamino)-1-methylpiperidine-4-carbonitrile

Catalog No.: 
ACMLPD261
CAS No.: 
1018435-91-0
Molecular Formula: 
C12H21N3
Molecular Weight: 
207.32
4-(Cyclopentylamino)-1-methylpiperidine-4-carbonitrile structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$132.00InquiryInquiry
100mg95%$187.00InquiryInquiry
250mg95%$261.00InquiryInquiry
1g95%$317.00InquiryInquiry
5g95%$937.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-(Cyclopentylamino)-1-methylpiperidine-4-carbonitrile
IUPAC Name4-(cyclopentylamino)-1-methylpiperidine-4-carbonitrile
MDL No.MFCD09959882
Molecular FormulaC12H21N3
Molecular Weight207.32
SMILESN#CC1(NC2CCCC2)CCN(C)CC1
InChI KeyFGLROCZMFJKOCX-UHFFFAOYSA-N
Synonym4-(cyclopentylamino)-1-methylpiperidine-4-carbonitrile;4-Piperidinecarbonitrile, 4-(cyclopentylamino)-1-methyl-
CAS No.1018435-91-0

Synthetic Route by SureRoute

1. ACMLPD261 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Plus
  5. ACFXPJ467 route compound structure diagram
    ACFXPJ46713963-58-1In Stock
  6. Then
  7. ACMLPD261 route product structure diagram
    ACMLPD2611018435-91-0
Inquiry

2. ACMLPD261 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACMLPD261 route product structure diagram
    ACMLPD2611018435-91-0
Inquiry

3. ACMLPD261 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACMLPD261 route product structure diagram
    ACMLPD2611018435-91-0
Inquiry

Comments (0)